Redhill Biopharma (STU:2RH0) Interest Expense : €-35.62 Mil (TTM As of Jun. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Redhill Biopharma Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Redhill Biopharma's interest expense for the three months ended in Jun. 2023 was € -1.78 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2023 was €-35.62 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Redhill Biopharma's Operating Income for the three months ended in Jun. 2023 was € -4.07 Mil. Redhill Biopharma's Interest Expense for the three months ended in Jun. 2023 was € -1.78 Mil. Redhill Biopharma did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Redhill Biopharma Interest Expense Historical Data

The historical data trend for Redhill Biopharma's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redhill Biopharma Interest Expense Chart

Redhill Biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.35

-10.23

-14.66

-39.02

-0.34

Redhill Biopharma Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23
Interest Expense	Get a 7-Day Free Trial															-32.10	-1.35	-0.39	-1.78	-

Redhill Biopharma Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-35.62 Mil.

Redhill Biopharma (STU:2RH0) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Redhill Biopharma's Interest Expense for the three months ended in Jun. 2023 was €-1.78 Mil. Its Operating Income for the three months ended in Jun. 2023 was €-4.07 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Jun. 2023 was €0.92 Mil.

Redhill Biopharma's Interest Coverage for the quarter that ended in Jun. 2023 is calculated as

Redhill Biopharma did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Redhill Biopharma (STU:2RH0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Redhill Biopharma Ltd (STU:2RH0) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

RDHL:USA 2RH0:Germany

Address

21 Ha’arba’a Street, Tel Aviv, ISR, 6473921

Website

https://www.redhillbio.com

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.

Redhill Biopharma (STU:2RH0) Headlines

No Headlines